Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
10-day versus 15-day dydrogesterone regimens for ovulatory abnormal uterine bleeding
IRCT20260521069469N1Phase 3Recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of dydrogesterone in abnormal uterine bleeding (AUB) and dysfunctional uterine bleeding (DUB) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: PBAC score, Number of bleeding days and 2 more. Started Sep 2025; status: recruiting.
02
Drugs
dydrogesterone
03
Conditions
abnormal uterine bleeding (AUB)dysfunctional uterine bleeding (DUB)
Beyond the preview
Go deeper on IRCT20260521069469N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260521069469N1.